摘要
目的:观察ER、PR和Her2/neu在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中的表达情况,并分析ER、PR和Her2/neu的表达与PTC的临床病理特征及其预后的关系。方法:采用免疫组化SP两步法检测108例PTC、20例甲状腺滤泡性腺瘤及10例正常甲状腺组织标本中ER、PR、Her2/neu的表达,采用荧光原位杂交技术检测Her2/neu基因的表达。结果:ER、PR在PTC组高表达,明显高于腺瘤组及正常组,应用免疫组化法和荧光原位杂交检测各组均未见Her2/neu表达;ER、PR、Her2/neu的表达与患者年龄、性别、淋巴结是否转移及患者预后无显著相关性。结论:ER、PR在PTC中表达敏感性较高,可以作为鉴别甲状腺良、恶性肿瘤的有效指标。Her2/neu在PTC中无表达,其与PTC患者预后无关,与Her2/neu相关的靶向治疗药物不可应用于PTC的治疗。
Objective：To evaluate the expression of ER,PR and Her2/neu, and to analyze the correlation between expression and clinical outcomes in papillary thyroid carcinoma. Methods： Immunohistoehemistry was used to detect the expression of ER, PR and Her2/neu, fluorescent in situ hybridization was used to detect the amplification state of Her2/neu gene in 108 cases of papillary thyroid carcinoma,20 cases of thyroid adenoma and 10 cases of normal thy- roid tissue. Results ： The expression of ER and PR were significally different between control group and PTC, the pro- tein expression and the gene amplification of Her2/neu were not detected by immunohistochemical technique or fluo- rescent in situ hybridization in the histological samples of papillary thyroid carcinoma,whereas ER, PR and Her2/neu had no correlation with the clinical features of papillary thyroid carcinoma. Conclusion： ER and PR are useful biomar- kers for the pathological diagnosis of PTC. Her2/neu is nonspecifie and has no contribution to the development of pa- pillary thyroid carcinoma. It can not be used as a molecular target for treatment of thyroid papillary carcinoma.
出处
《现代肿瘤医学》
CAS
2015年第24期3576-3579,共4页
Journal of Modern Oncology
基金
河北联合大学青年基金课题(编号:Z201338)
